Mild Renal Dysfunction and Metabolites Tied to Low HDL Cholesterol Are Associated With Monocytosis and Atherosclerosis

Background— The number of circulating blood monocytes impacts atherosclerotic lesion size, and in mouse models, elevated levels of high-density lipoprotein cholesterol suppress blood monocyte counts and atherosclerosis. We hypothesized that individuals with mild renal dysfunction at increased cardiovascular risk would have reduced high-density lipoprotein levels, high blood monocyte counts, and accelerated atherosclerosis. Methods and Results— To test whether mild renal dysfunction is associated with an increase in a leukocyte subpopulation rich in monocytes that has a known association with future coronary events, we divided individuals from the Malmö Diet and Cancer study (MDC) into baseline cystatin C quintiles (n=4757). Lower levels of renal function were accompanied by higher monocyte counts, and monocytes were independently associated with carotid bulb intima-media thickness cross-sectionally (P=0.02). Cystatin C levels were positively and plasma high-density lipoprotein cholesterol levels negatively associated with monocyte counts at baseline, after adjustment for traditional risk factors. Several amino acid metabolites tied to low levels of high-density lipoprotein cholesterol and insulin resistance measured in a subset of individuals (n=752) by use of liquid chromatography–mass spectrometry were independently associated with a 22% to 34% increased risk of being in the top quartile of monocytes (P<0.05). Conclusions— A low high-density lipoprotein cholesterol, insulin resistance phenotype occurs in subjects with mild renal dysfunction and is associated with elevated monocytes and atherosclerosis. High blood monocyte counts may represent a previously unrecognized mechanism underlying the strong relationship between cystatin C and cardiovascular risk.

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  Thomas J. Wang,et al.  A diabetes-predictive amino acid score and future cardiovascular disease. , 2013, European heart journal.

[3]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[4]  R. Vasan,et al.  Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans , 2012, Circulation.

[5]  D. Panagiotakos,et al.  Association between serum cystatin C, monocytes and other inflammatory markers , 2012, Internal medicine journal.

[6]  O. Melander,et al.  Incidence of Coronary Events and Case Fatality Rate in Relation to Blood Lymphocyte and Neutrophil Counts , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[7]  B. Chaitman,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[8]  A. Hirayama,et al.  Serum cystatin C is associated with early stage coronary atherosclerotic plaque morphology on multidetector computed tomography. , 2011, Atherosclerosis.

[9]  Josef Coresh,et al.  Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  D. Herrington,et al.  The Association of Chronic Kidney Disease and Metabolic Syndrome with Incident Cardiovascular Events: Multiethnic Study of Atherosclerosis , 2011, Cardiology research and practice.

[11]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[12]  Y. Marcel,et al.  Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. , 2011, Cell metabolism.

[13]  Robert P Light,et al.  Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[14]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[15]  A. Tall,et al.  ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation , 2010, Science.

[16]  Xuefeng Sun,et al.  Lack of independent relationship between age-related kidney function decline and carotid intima-media thickness in a healthy Chinese population. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  Jean-Claude Tardif,et al.  Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. , 2009, American heart journal.

[18]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[19]  H. Parving,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[20]  J. Polak,et al.  Cystatin C and carotid intima-media thickness in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  T. P. Neufeld,et al.  Nutrient-dependent regulation of autophagy through the target of rapamycin pathway. , 2009, Biochemical Society transactions.

[22]  F. Burzotta,et al.  Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. , 2008, Atherosclerosis.

[23]  T. Simon,et al.  Combined Inhibition of CCL2, CX3CR1, and CCR5 Abrogates Ly6Chi and Ly6Clo Monocytosis and Almost Abolishes Atherosclerosis in Hypercholesterolemic Mice , 2008, Circulation.

[24]  A. Schlitt,et al.  CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. , 2008, Kidney international.

[25]  R. Cahill,et al.  Prediction of calculated future cardiovascular disease by monocyte count in an asymptomatic population , 2008, Vascular health and risk management.

[26]  K. Chow,et al.  Carotid intima media thickness predicts cardiovascular diseases in Chinese predialysis patients with chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[27]  P. Libby,et al.  Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. , 2007, The Journal of clinical investigation.

[28]  E. Kang,et al.  The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. , 2006, Diabetes research and clinical practice.

[29]  B. Kestenbaum,et al.  Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease , 2006, Annals of Internal Medicine.

[30]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[31]  D. Siscovick,et al.  Cystatin C and the risk of death and cardiovascular events among elderly persons. , 2005, The New England journal of medicine.

[32]  R. Nelson,et al.  Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. , 2005, Journal of the American Society of Nephrology : JASN.

[33]  O. Joakimsen,et al.  Monocyte Count Is a Predictor of Novel Plaque Formation: A 7-Year Follow-up Study of 2610 Persons Without Carotid Plaque at Baseline The Tromsø Study , 2005, Stroke.

[34]  A. Folsom,et al.  Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. , 2005, Journal of the American Society of Nephrology : JASN.

[35]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[36]  B. Franklin,et al.  Renal dysfunction and acceleration of coronary disease , 2004, Heart.

[37]  J. Beilby,et al.  Monocyte Count, But Not C-Reactive Protein or Interleukin-6, Is an Independent Risk Marker for Subclinical Carotid Atherosclerosis , 2004, Stroke.

[38]  A. Hishida,et al.  Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. , 2003, Kidney international.

[39]  N. Day,et al.  Smoking status and differential white cell count in men and women in the EPIC-Norfolk population. , 2003, Atherosclerosis.

[40]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[41]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[42]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[43]  J. Scherberich,et al.  Expanded CD14+ CD16+Monocyte Subpopulation in Patients with Acute and Chronic Infections Undergoing Hemodialysis , 1998, Infection and Immunity.

[44]  G. Pacini,et al.  Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. , 1998, Kidney international.

[45]  C. Kahn,et al.  Bidirectional modulation of insulin action by amino acids. , 1998, The Journal of clinical investigation.

[46]  P. D. de Feyter,et al.  Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. , 1997, Stroke.

[47]  P. Nestel,et al.  Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.

[48]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[49]  P. P. Toth Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy , 2012 .

[50]  D. Fliser,et al.  CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. , 2011, European heart journal.

[51]  B. Astor,et al.  Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[52]  E. Bonora,et al.  Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. , 2000, Diabetes care.